Level Four Advisory Services’s Actinium Pharmaceuticals ATNM Stock Holding History

Level Four Advisory Services’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.95K	Hold	10,000	–	–	﹤0.01%	866
2025 Q4	$13.6K	Hold	10,000	–	–	﹤0.01%	841
2025 Q3	$16K	Buy	+10,000	New	+$16.3K	﹤0.01%	801

Other funds holding ATNM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Level Four Advisory Services's ATNM Position: Q1 2026 in Review

Level Four Advisory Services held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 10,000 shares worth $9.95K. The position accounts for ﹤0.01% of the portfolio, ranked #866.

Level Four Advisory Services first reported a position in ATNM in Q3 2025 and has held it in 3 quarters since. The position peaked at $16K in Q3 2025. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.

Level Four Advisory Services held 10,000 shares of Actinium Pharmaceuticals worth $9.95K as of Q1 2026.
Level Four Advisory Services left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
Actinium Pharmaceuticals made up ﹤0.01% of Level Four Advisory Services's portfolio in Q1 2026, its #866 holding.
Level Four Advisory Services first reported a position in Actinium Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
Level Four Advisory Services's Actinium Pharmaceuticals position peaked at $16K in Q3 2025.
54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.

Based on Level Four Advisory Services's 13F filing for Q1 2026, filed 14 May 2026.